ArticleAntibiotics (Basel, Switzerland)2023
Site Mutation Improves the Expression and Antimicrobial Properties of Fungal Defense.
Article in Antibiotics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Molecular action of NZ2114, a superior plectasin derivative.npj antimicrobials and resistance · 2026Article
- A Comprehensive Overview of Antimicrobial Peptides: Broad-Spectrum Activity, Computational Approaches, and Applications.Antibiotics (Basel, Switzerland) · 2025Review
- Expression and characterization of the new antimicrobial peptide AP138L-arg26 anti Staphylococcus aureus.Applied microbiology and biotechnology · 2024Article
- The Marine Antimicrobial Peptide AOD with Intact Disulfide Bonds Has Remarkable Antibacterial and Anti-Biofilm Activity.Marine drugs · 2024Article
- Pharmacokinetics and pharmacodynamics of antibacterial peptide NZX in Staphylococcus aureus mastitis mouse model.Applied microbiology and biotechnology · 2024Article
- Polylactic Glycolic Acid-Mediated Delivery of Plectasin Derivative NZ2114 inAntibiotics (Basel, Switzerland) · 2024Article
- Editorial: Antimicrobial peptides and their druggability, bio-safety, stability, and resistance.Frontiers in microbiology · 2024Article
- High-Yield Preparation of American Oyster Defensin (AOD) via a Small and Acidic Fusion Tag and Its Functional Characterization.Marine drugs · 2023Article
- Plectasin: from evolution to truncation, expression, and better druggability.Frontiers in microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Although antimicrobial peptides (AMPs) have highly desirable intrinsic characteristics in their commercial product development as new antimicrobials, the limitations of AMPs from experimental to scale development include the low oral bioavailability, and high production costs due to inadequate in vitro/in vivo gene expression- and low scale. Plectasin has good bactericidal activity against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.